Rhenman & Partners Asset Management AB Has $157,000 Position in Sunesis Pharmaceuticals, Inc. (SNSS)

Share on StockTwits

Rhenman & Partners Asset Management AB cut its holdings in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by 11.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 377,244 shares of the biopharmaceutical company’s stock after selling 50,398 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Sunesis Pharmaceuticals were worth $157,000 as of its most recent SEC filing.

SNSS has been the subject of several analyst reports. Zacks Investment Research downgraded Sunesis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 10th. ValuEngine downgraded Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 15th. Finally, HC Wainwright initiated coverage on Sunesis Pharmaceuticals in a research report on Thursday, December 20th. They issued a “neutral” rating and a $0.50 target price for the company. Five investment analysts have rated the stock with a hold rating, The stock presently has an average rating of “Hold” and a consensus price target of $1.67.

Shares of SNSS opened at $0.49 on Tuesday. The stock has a market capitalization of $18.34 million, a P/E ratio of -0.34 and a beta of 2.69. Sunesis Pharmaceuticals, Inc. has a one year low of $0.20 and a one year high of $7.69.

COPYRIGHT VIOLATION WARNING: “Rhenman & Partners Asset Management AB Has $157,000 Position in Sunesis Pharmaceuticals, Inc. (SNSS)” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4146488/rhenman-partners-asset-management-ab-has-157000-position-in-sunesis-pharmaceuticals-inc-snss.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

See Also: Earnings Per Share (EPS)

Want to see what other hedge funds are holding SNSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS).

Institutional Ownership by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Twitter Inc  Stake Lifted by Skylands Capital LLC
Twitter Inc Stake Lifted by Skylands Capital LLC
Monarch Partners Asset Management LLC Buys Shares of 567,333 Ladder Capital Corp
Monarch Partners Asset Management LLC Buys Shares of 567,333 Ladder Capital Corp
Monarch Partners Asset Management LLC Purchases 33,854 Shares of WNS  Limited
Monarch Partners Asset Management LLC Purchases 33,854 Shares of WNS Limited
Parkwood LLC Purchases New Position in EnLink Midstream LLC
Parkwood LLC Purchases New Position in EnLink Midstream LLC
Monarch Partners Asset Management LLC Grows Stake in Carrols Restaurant Group, Inc.
Monarch Partners Asset Management LLC Grows Stake in Carrols Restaurant Group, Inc.
Parkwood LLC Has $772,000 Holdings in Ceridian HCM Holding Inc
Parkwood LLC Has $772,000 Holdings in Ceridian HCM Holding Inc


Leave a Reply

© 2006-2019 Ticker Report